Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720174 · ClinicalTrials.gov registry record · Phase 1
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 13
- Study locations
NCT00720174: Completed Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma, sponsored by National Cancer Institute (NCI).
NCT00720174 is a Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720174, a Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 13
- Study locations
Study Summary
This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.
Primary Outcome
The MTD is defined as the dose of Cixitumumab that induces dose-limiting toxicity (DLT) in no more than 20% of patients.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Cixutumumab
Study Locations (13)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Joliet Oncology-Hematology Associates Limited - Joliet
- Loyola University Medical Center - Maywood
- Illinois CancerCare-Peoria - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Missouri
- Mercy Hospital Saint Louis - St Louis
Wisconsin
- Froedtert and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-06 |
| Phase | Phase 1 |
What the finished NCT00720174 record still lists
NCT00720174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 10 conditions, with Adult Angiosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00720174 lists 13 locations in 6 states (Illinois, Indiana, Maryland).
Frequently Asked Questions
What is clinical trial NCT00720174 about?
NCT00720174 is a clinical study titled "Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma". This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block ...
What is the current status of trial NCT00720174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-06.
What conditions does trial NCT00720174 study?
This clinical trial studies the following conditions: Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Desmoplastic Small Round Cell Tumor.
What interventions are being tested in trial NCT00720174?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00720174?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00720174 being conducted?
This trial has 13 study locations across Illinois, Indiana, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Angiosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00720174's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia